Straits Times Index
3,385.93 +1.64 (+0.05%) S&P 500
4,116.89 -19.59 (-0.47%) Dow
33,918.04 -7.97 (-0.02%) Nasdaq
11,923.82 -83.14 (-0.69%) BTC-USD
23,036.47 +174.83 (+0.76%) CMC Crypto 200
529.44 +4.31 (+0.82%)
Roche Holding AG (RHHVF)
| Previous close | 302.77 |
| Open | 309.13 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 300.77 - 309.13 |
| 52-week range | 298.00 - 430.00 |
| Volume | |
| Avg. volume | 6,596 |
| Market cap | 252.413B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 15.61 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 10.47 (3.46%) |
| Ex-dividend date | 16 Mar 2023 |
| 1y target est | N/A |
- Business Wire
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
SOUTH SAN FRANCISCO, Calif., January 19, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study is evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence. The Tec
- Business Wire
FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif., January 06, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. LBC
- Business Wire
FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma
SOUTH SAN FRANCISCO, Calif., December 23, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Lunsumio® (mosunetuzumab-axgb) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingen
